Clinical Trial Update: ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial ELVN-002 for HER2-mutant non-small cell lung cancer and HER2-positive metastatic breast cancer is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• ELVN-002

Snippet

Sponsor: Enliven Therapeutics | Conditions: HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING